Clinical trials: Autoimmune Pulmonary Alveolar Proteinosis, active
Autoimmune Pulmonary Alveolar Proteinosis
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks.
- Trial name
- IMPALA-2 (NCT04544293)
- Testing
- Molgramostim, Molgramostim Open-label
- Where
- 54 sites in United States, Australia and 16 more
- Volunteers
- 164 people
- Sponsor
- Savara Inc.
Autoimmune Pulmonary Alveolar Proteinosis
A Study of hBMMSC Injection in Patients With aPAP
The purpose of this multicenter, randomized, double-blind, placebo-controlled phase IIb clinical trial is to evaluate the efficacy and safety of intravenous hBMMSC injection in patients with autoimmune pulmonary alveolar…
- Trial name
- NCT07890649
- Testing
- The human Bone Marrow Mesenchymal Stem Cell (hBMMSC) injection, Lactated Ringer's Injection (crystalloid)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Autoimmune Pulmonary Alveolar Proteinosis
Study of Human Bone Marrow Mesenchymal Stem Cells in APAP
The purpose of this open-label phase IIa clinical trial study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP.
- Trial name
- NCT06111846
- Testing
- human Bone Marrow Mesenchymal Stem Cell (hBMMSC)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18.
- Trial name
- NCT06431776
- Testing
- Molgramostim
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Savara Inc.
Pulmonary Alveolar Proteinosis
Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis
This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.
- Trial name
- aPAP and GMCSF (NCT06989333)
- Testing
- GM-CSF (granulocyte-macrophage colony-stimulating factor)
- Volunteers
- 10 people
- Sponsor
- Jiuwu Bai